I will go one step further - and suggest it is apparent now in my view, as to why paxalisib did not go forward to the next stage in GBM AGILE.
Paxalisib hobbled in all their GBM studies so far - without this strong emphasis to have patients cut insulin levels.
- how about come on with your views on something just a little more technical here this time.
Lets here it - what have others got.
